The Latest: 'Pharma Bro' jury to begin deliberations Monday

Former biotech CEO Martin Shkreli, right, leaves federal court with a member of his legal team Thursday, July 27, 2017, in New York. Shkreli's defense attorney, Benjamin Brafman, told the jury during closing arguments that his client annoyed some of his investors but ultimately rewarded them by starting a drug company that doubled or tripled their money. (AP Photo/Julie Jacobson)

NEW YORK — The Latest on the securities fraud trial of Martin Shkreli (all times local):

4 p.m.

Jurors at the securities fraud trial of "Pharma Bro" Martin Shkreli will begin deliberations on Monday.

A judge instructed the jury on the law for most of the afternoon on Friday before sending jurors home for the weekend.

Earlier in the day, the jury heard closing arguments by prosecutors accusing the former pharmaceutical CEO looted his own drug company to pay back disgruntled investors in two failed hedge funds he ran. The defense insisted there are no victims because everyone got their original investments back and even made hefty profits.

The 34-year-old Shkreli is best known for jacking up the price of a life-saving drug by 5,000 percent and for trolling his critics online.

___

11 a.m.

A prosecutor says a securities fraud trial has exposed "Pharma Bro" Martin Shkreli as a "con man."

Assistant U.S. Attorney Jacquelyn Kasulis said in closing arguments Friday that the evidence at the trial in federal court in New York City proved the former pharmaceutical CEO looted his own drug company to pay back disgruntled investors in two failed hedge funds he ran.

The defense argued that a drug company official who testified for the government was biased because if Shkreli is found guilty of a felony, the company could justify his firing in 2014 and gain ammunition in its $65 million lawsuit against him.

Shkreli is best known for jacking up the price of a life-saving drug by 5,000 percent and for trolling his critics online.

___

This story has been corrected to show that $65 million refers to damages sought in a lawsuit, not a $65 million stake in a drug company.

Must Read

Twins trumped: Winklevoss's lose bid for bitcoin trade fund

Mar 11, 2017

The irrepressible Winklevoss twins, known for having sued Mark Zuckerberg over the idea for Facebook, have suffered a setback from federal regulators in their push to expand the use of bitcoin to a wider universe of investors

General Motors rejects investor plan for 2 stock classes

Mar 28, 2017

General Motors says it has rejected a proposal from investor David Einhorn to split its stock into two classes

Senate Dems press Trump's wealthy picks for financial data

Dec 22, 2016

Top Senate Democrats are trying to put the brakes on President-elect Donald Trump's Cabinet picks, insisting on financial disclosure statements and background checks on some of the wealthiest Americans before moving forward on nominations

People also read these

Twins trumped: Winklevoss's lose bid for bitcoin trade fund

Mar 11, 2017

The irrepressible Winklevoss twins, known for having sued Mark Zuckerberg over the idea for Facebook, have suffered a setback from federal regulators in their push to expand the use of bitcoin to a wider universe of investors

General Motors rejects investor plan for 2 stock classes

Mar 28, 2017

General Motors says it has rejected a proposal from investor David Einhorn to split its stock into two classes

Senate Dems press Trump's wealthy picks for financial data

Dec 22, 2016

Top Senate Democrats are trying to put the brakes on President-elect Donald Trump's Cabinet picks, insisting on financial disclosure statements and background checks on some of the wealthiest Americans before moving forward on nominations